However, for attempts to treat diabetes in humans with CCK receptor agonists, for safety reasons [146], it has to be low doses of the agonist in combination with analogues of the major incretins such as GLP‐1 and GIP (for review, see ref. [129]). This evidence concerns the gene GCG and diabetes mellitus.